Risk factors for late recurrence after 5-year adjuvant endocrine therapy
What is it about?
Currently,although several clinical trials available give strong suggestions that extension of endocrine therapy has benefits, the risk level at which patients may benefit from extended endocrine therapy remains uncertain. We conducted this study to identify the amount of patients at a substantial risk of late recurence after 5-year adjuvant endocrine therapy that might benefit from extended endocrine therapy.
Why is it important?
Our findings show that late relapse after completion of 5-year adjuvant endocrine therapy was still common, grade 3 and more than 3 positive nodes were risk factors of late recurrence, while grade 3 was the only risk factor of late distant metastasis, these patients might benefit from extended endocrine therapy.
The following have contributed to this page: Junming Xu, Ye Wang, Junyi Wu, Jun Qin, Min Wang, and Tao jin